Exosomes are endogenous nanoparticles that can deliver biological information between cells

Advanced Drug Delivery Reviews

Volumn 65, Issue 3, 2013, Pages 342-347

  Sun, Dongmei ^a   Zhuang, Xiaoying ^b   Zhang, Shuangqin ^a   Deng, Zhong Bin ^b   Grizzle, William ^d   Miller, Donald ^b   Zhang, Huang Ge ^b,c  

^a and Clinical Center   (United States)

^b University of Louisville School of Medicine   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Exosome delivery vehicle; Immune regulation; Nanoparticles

Indexed keywords

BIOLOGICAL EFFECTS; BIOLOGICAL INFORMATION; DELIVERY VEHICLE; DRUG CARRIER; HOST CELLS; IMMUNE REGULATION; NANOPARTICLE SIZES; PERSONALIZED MEDICINES;

CYTOTOXICITY; DRUG DELIVERY;

NANOPARTICLES;

CURCUMIN; DOXORUBICIN; DRUG CARRIER; LIPOSOME; NANOPARTICLE; TRANSFERRIN RECEPTOR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; EXOSOME; HOST CELL; HUMAN; HYDROPHOBICITY; IMMUNE RESPONSE; LIPID BILAYER; PARTICLE SIZE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EXOSOMES; HUMANS; IMMUNOMODULATION; INDIVIDUALIZED MEDICINE; NANOPARTICLES; PARTICLE SIZE;

EID: 84874969474     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.07.002     Document Type: Review

References (89)

1. Rodgers P. Back to the future. Nat. Nanotechnol. 2011, 6:607-608.
2. Toumey C. In the footsteps of biotech. Nat. Nanotechnol. 2010, 5:475.
3. Rosa G.D., Salzano G., Caraglia M., Saccardi A.A. Nanotechnologies: a strategy to overcome blood-brain barrier. Curr. Drug Metab. Jan 2012, 13(1):61-69.
4. Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm. Res. 2010, 27:1759-1771.
5. Bonoiu A.C., Mahajan S.D., Ding H., Roy I., Yong K.T., Kumar R., Hu R., Bergey E.J., Schwartz S.A., Prasad P.N. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5546-5550.
6. Papakostas D., Rancan F., Sterry W., Blume-Peytavi U., Vogt A. Nanoparticles in dermatology. Arch. Dermatol. Res. 2011, 303:533-550.
7. Prow T.W., Chen X., Prow N.A., Fernando G.J., Tan C.S., Raphael A.P., Chang D., Ruutu M.P., Jenkins D.W., Pyke A., Crichton M.L., Raphaelli K., Goh L.Y., Frazer I.H., Roberts M.S., Gardner J., Khromykh A.A., Suhrbier A., Hall R.A., Kendall M.A. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 2010, 6:1776-1784.
8. Bakand S., Hayes A., Dechsakulthorn F. Nanoparticles: a review of particle toxicology following inhalation exposure. Inhal. Toxicol. 2012, 24:125-135.
9. Iavicoli I., Leso V., Fontana L., Bergamaschi A. Toxicological effects of titanium dioxide nanoparticles: a review of in vitro mammalian studies. Eur. Rev. Med. Pharmacol. Sci. 2011, 15:481-508.
10. Maynard A.D. Don't define nanomaterials. Nature 2011, 475:31.
11. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9:581-593.
12. Johnstone R.M. The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem. Cell Biol. 1992, 70:179-190.
13. Zhuang X., Xiang X., Grizzle W., Sun D., Zhang S., Axtell R.C., Ju S., Mu J., Zhang L., Steinman L., Miller D., Zhang H.G. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 2011, 19:1769-1779.
14. Sun D., Zhuang X., Xiang X., Liu Y., Zhang S., Liu C., Barnes S., Grizzle W., Miller D., Zhang H.G. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 2010, 18:1606-1614.
15. Campbell F.C., Collett G.P. Chemopreventive properties of curcumin. Future Oncol. 2005, 1:405-414.
16. Thomasset S.C., Berry D.P., Garcea G., Marczylo T., Steward W.P., Gescher A.J. Dietary polyphenolic phytochemicals-promising cancer chemopreventive agents in humans? A review of their clinical properties. Int. J. Cancer 2006, 120:451-458.
17. Tomita M., Matsuda T., Kawakami H., Uchihara J.N., Okudaira T., Masuda M., Ohshiro K., Mori N. Curcumin targets Akt cell survival signaling pathway in HTLV-I-infected T-cell lines. Cancer Sci. 2006, 97:322-327.
18. Wright T.I., Spencer J.M., Flowers F.P. Chemoprevention of nonmelanoma skin cancer. J. Am. Acad. Dermatol. 2006, 54:933-946. (quiz 947-950).
19. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29:341-345.
20. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat. Rev. Cancer 2009, 9:40-55.
21. Matsumura Y., Oda T., Maeda H. General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics. Gan To Kagaku Ryoho 1987, 14:821-829.
22. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
23. Geiser M., Casaulta M., Kupferschmid B., Schulz H., Semmler-Behnke M., Kreyling W. The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles. Am. J. Respir. Cell Mol. Biol. 2008, 38:371-376.
24. Kuhlbusch T.A., Asbach C., Fissan H., Gohler D., Stintz M. Nanoparticle exposure at nanotechnology workplaces: a review. Part. Fibre Toxicol. 2011, 8:22.
25. Almeida J.P., Chen A.L., Foster A., Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine (Lond.) 2011, 6:815-835.
26. Saha R.N., Vasanthakumar S., Bende G., Snehalatha M. Nanoparticulate drug delivery systems for cancer chemotherapy. Mol. Membr. Biol. 2010, 27:215-231.
27. Bryant R.J., Pawlowski T., Catto J.W., Marsden G., Vessella R.L., Rhees B., Kuslich C., Visakorpi T., Hamdy F.C. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 2012, 106:768-774.
28. Wittmann J., Jack H.M. Serum microRNAs as powerful cancer biomarkers. Biochim. Biophys. Acta 2010, 1806:200-207.
29. Kosaka N., Iguchi H., Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101:2087-2092.
30. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., Curry W.T., Carter B.S., Krichevsky A.M., Breakefield X.O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10:1470-1476.
31. Yang Y., Liu X., Zhang D., Yu W., Lv G., Xie H., Zheng J., Ma X. Chitosan/VEGF-sIRNA nanoparticle for gene silencing. J. Control. Release 2011, 152(Suppl. 1):e160-e161.
32. Leng A., Yang J., Liu T., Cui J., Li X.H., Zhu Y., Xiong T., Chen Y. Nanoparticle-delivered VEGF-silencing cassette and suicide gene expression cassettes inhibit colon carcinoma growth in vitro and in vivo. Tumour Biol. 2011, 32:1103-1111.
33. Chen Y., Zhu X., Zhang X., Liu B., Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 2010, 18:1650-1656.
34. Jin Y., Song Y., Zhu X., Zhou D., Chen C., Zhang Z., Huang Y. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 2012, 33:1573-1582.
35. Paliwal R., Paliwal S.R., Agrawal G.P., Vyas S.P. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: in vitro and in vivo evaluation. Int. J. Pharm. 2012, 422:179-184.
36. Duarte V.M., Han E., Veena M.S., Salvado A., Suh J.D., Liang L.J., Faull K.F., Srivatsan E.S., Wang M.B. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKbeta protein of the NFkappaB pathway. Mol. Cancer Ther. 2010, 9:2665-2675.
37. Pan D., Turner J.L., Wooley K.L. Folic acid-conjugated nanostructured materials designed for cancer cell targeting. Chem. Commun. (Camb.) 2003, 2400-2401.
38. Stella B., Arpicco S., Peracchia M.T., Desmaele D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 2000, 89:1452-1464.
39. Zaki N.M., Nasti A., Tirelli N. Nanocarriers for cytoplasmic delivery: cellular uptake and intracellular fate of chitosan and hyaluronic acid-coated chitosan nanoparticles in a phagocytic cell model. Macromol. Biosci. 2011, 11:1747-1760.
40. Kamat M., El-Boubbou K., Zhu D.C., Lansdell T., Lu X., Li W., Huang X. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconjug. Chem. 2010, 21:2128-2135.
41. Le Guevel X., Daum N., Schneider M. Synthesis and characterization of human transferrin-stabilized gold nanoclusters. Nanotechnology 2011, 22:275103.
42. Yu B., Tai H.C., Xue W., Lee L.J., Lee R.J. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol. Membr. Biol. 2010, 27:286-298.
43. Zheng Y., Yu B., Weecharangsan W., Piao L., Darby M., Mao Y., Koynova R., Yang X., Li H., Xu S., Lee L.J., Sugimoto Y., Brueggemeier R.W., Lee R.J. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int. J. Pharm. 2010, 390:234-241.
44. Zhang X., Koh C.G., Yu B., Liu S., Piao L., Marcucci G., Lee R.J., Lee L.J. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model. Pharm. Res. 2009, 26:1516-1524.
45. Zhang C., Pei J., Kumar D., Sakabe I., Boudreau H.E., Gokhale P.C., Kasid U.N. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. Methods Mol. Biol. 2007, 361:163-185.
46. Park K. Lectin-immobilized nanospheres for GI tumor targeting. J. Control. Release 2009, 134:1.
47. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 2000, 11:1-18.
48. Vyas T.K., Shahiwala A., Marathe S., Misra A. Intranasal drug delivery for brain targeting. Curr. Drug Deliv. 2005, 2:165-175.
49. Zhang Y., Luo C.L., He B.C., Zhang J.M., Cheng G., Wu X.H. Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma. Int. J. Oncol. 2010, 36:133-140.
50. Caserta M.T., Caccioppo D., Lapin G.D., Ragin A., Groothuis D.R. Blood-brain barrier integrity in Alzheimer's disease patients and elderly control subjects. J. Neuropsychiatry Clin. Neurosci. 1998, 10:78-84.
51. Xiang X., Liu Y., Zhuang X., Zhang S., Michalek S., Taylor D.D., Grizzle W., Zhang H.G. TLR2-mediated expansion of MDSCs is dependent on the source of tumor exosomes. Am. J. Pathol. 2010, 177:1606-1610.
52. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., Boireau W., Rouleau A., Simon B., Lanneau D., De Thonel A., Multhoff G., Hamman A., Martin F., Chauffert B., Solary E., Zitvogel L., Garrido C., Ryffel B., Borg C., Apetoh L., Rebe C., Ghiringhelli F. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010, 120:457-471.
53. Szajnik M., Czystowska M., Szczepanski M.J., Mandapathil M., Whiteside T.L. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One 2010, 5:e11469.
54. Xiang X., Poliakov A., Liu C., Liu Y., Deng Z.B., Wang J., Cheng Z., Shah S.V., Wang G.J., Zhang L., Grizzle W.E., Mobley J., Zhang H.G. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer 2009, 124:2621-2633.
55. Valenti R., Huber V., Iero M., Filipazzi P., Parmiani G., Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007, 67:2912-2915.
56. Zhang H.G., Liu C., Su K., Yu S., Zhang L., Zhang S., Wang J., Cao X., Grizzle W., Kimberly R.P. A membrane form of TNF-alpha presented by exosomes delays T cell activation-induced cell death. J. Immunol. 2006, 176:7385-7393.
57. Liu C., Yu S., Zinn K., Wang J., Zhang L., Jia Y., Kappes J.C., Barnes S., Kimberly R.P., Grizzle W.E., Zhang H.G. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 2006, 176:1375-1385.
58. Whiteside T.L. Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system?. Br. J. Cancer 2005, 92:209-211.
59. Altieri S.L., Khan A.N., Tomasi T.B. Exosomes from plasmacytoma cells as a tumor vaccine. J. Immunother. 2004, 27:282-288.
60. Andre F., Schartz N.E., Chaput N., Flament C., Raposo G., Amigorena S., Angevin E., Zitvogel L. Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine 2002, 20(Suppl. 4):A28-A31.
61. Wolfers J., Lozier A., Raposo G., Regnault A., Thery C., Masurier C., Flament C., Pouzieux S., Faure F., Tursz T., Angevin E., Amigorena S., Zitvogel L. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001, 7:297-303.
62. Andre F., Chaput N., Schartz N.E., Flament C., Aubert N., Bernard J., Lemonnier F., Raposo G., Escudier B., Hsu D.H., Tursz T., Amigorena S., Angevin E., Zitvogel L. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. 2004, 172:2126-2136.
63. Hsu D.H., Paz P., Villaflor G., Rivas A., Mehta-Damani A., Angevin E., Zitvogel L., Le Pecq J.B. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J. Immunother. 2003, 26:440-450.
64. Del Cacho E., Gallego M., Lee S.H., Lillehoj H.S., Quilez J., Lillehoj E.P., Sanchez-Acedo C. Induction of protective immunity against Eimeria tenella infection using antigen-loaded dendritic cells (DC) and DC-derived exosomes. Vaccine 2011, 29:3818-3825.
65. Nanjundappa R.H., Wang R., Xie Y., Umeshappa C.S., Chibbar R., Wei Y., Liu Q., Xiang J. GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses. Vaccine 2011, 29:3538-3547.
66. Montecalvo A., Larregina A.T., Shufesky W.J., Beer Stolz D., Sullivan M.L., Karlsson J.M., Baty C.J., Gibson G.A., Erdos G., Wang Z., Milosevic J., Tkacheva O.A., Divito S.J., Jordan R., Lyons-Weiler J., Watkins S.C., Morelli A.E. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 2012, 119:756-766.
67. Hartman Z.C., Wei J., Glass O.K., Guo H., Lei G., Yang X.Y., Osada T., Hobeika A., Delcayre A., Le Pecq J.B., Morse M.A., Clay T.M., Lyerly H.K. Increasing vaccine potency through exosome antigen targeting. Vaccine 2011, 29:9361-9367.
68. Viaud S., Ploix S., Lapierre V., Thery C., Commere P.H., Tramalloni D., Gorrichon K., Virault-Rocroy P., Tursz T., Lantz O., Zitvogel L., Chaput N. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-gamma. J. Immunother. 2011, 34:65-75.
69. Ashiru O., Boutet P., Fernandez-Messina L., Aguera-Gonzalez S., Skepper J.N., Vales-Gomez M., Reyburn H.T. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 2010, 70:481-489.
70. Yu S., Liu C., Su K., Wang J., Liu Y., Zhang L., Li C., Cong Y., Kimberly R., Grizzle W.E., Falkson C., Zhang H.G. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 2007, 178:6867-6875.
71. Wang G.J., Liu Y., Qin A., Shah S.V., Deng Z.B., Xiang X., Cheng Z., Liu C., Wang J., Zhang L., Grizzle W.E., Zhang H.G. Thymus exosomes-like particles induce regulatory T cells. J. Immunol. 2008, 181:5242-5248.
72. + T-cell apoptosis. Blood Cells Mol. Dis. 2005, 35:169-173.
73. Klibi J., Niki T., Riedel A., Pioche-Durieu C., Souquere S., Rubinstein E., Le Moulec S., Guigay J., Hirashima M., Guemira F., Adhikary D., Mautner J., Busson P. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009, 113:1957-1966.
74. Taylor D.D., Akyol S., Gercel-Taylor C. Pregnancy-associated exosomes and their modulation of T cell signaling. J. Immunol. 2006, 176:1534-1542.
75. Cai Z., Zhang W., Yang F., Yu L., Yu Z., Pan J., Wang L., Cao X., Wang J. Immunosuppressive exosomes from TGF-beta1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells. Cell Res. 2011, 22:607-610.
76. Bianco N.R., Kim S.H., Ruffner M.A., Robbins P.D. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum. 2009, 60:380-389.
77. Lai R.C., Arslan F., Lee M.M., Sze N.S., Choo A., Chen T.S., Salto-Tellez M., Timmers L., Lee C.N., El Oakley R.M., Pasterkamp G., de Kleijn D.P., Lim S.K. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010, 4:214-222.
78. Bakhti M., Winter C., Simons M. Inhibition of myelin membrane sheath formation by oligodendrocyte-derived exosome-like vesicles. J. Biol. Chem. 2011, 286:787-796.
79. Emmanouilidou E., Melachroinou K., Roumeliotis T., Garbis S.D., Ntzouni M., Margaritis L.H., Stefanis L., Vekrellis K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 2010, 30:6838-6851.
80. Fitzner D., Schnaars M., van Rossum D., Krishnamoorthy G., Dibaj P., Bakhti M., Regen T., Hanisch U.K., Simons M. Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis. J. Cell Sci. 2011, 124:447-458.
81. Potolicchio I., Carven G.J., Xu X., Stipp C., Riese R.J., Stern L.J., Santambrogio L. Proteomic analysis of microglia-derived exosomes: metabolic role of the aminopeptidase CD13 in neuropeptide catabolism. J. Immunol. 2005, 175:2237-2243.
82. Robertson C., Booth S.A., Beniac D.R., Coulthart M.B., Booth T.F., McNicol A. Cellular prion protein is released on exosomes from activated platelets. Blood 2006, 107:3907-3911.
83. Fevrier B., Vilette D., Archer F., Loew D., Faigle W., Vidal M., Laude H., Raposo G. Cells release prions in association with exosomes. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9683-9688.
84. Kamphorst A.O., Guermonprez P., Dudziak D., Nussenzweig M.C. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J. Immunol. 2010, 185:3426-3435.
85. Oussoren C., Zuidema J., Crommelin D.J., Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta 1997, 1328:261-272.
86. Champion J.A., Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4930-4934.
87. Ristorcelli E., Beraud E., Verrando P., Villard C., Lafitte D., Sbarra V., Lombardo D., Verine A. Human tumor nanoparticles induce apoptosis of pancreatic cancer cells. FASEB J. 2008, 22:3358-3369.
88. Ristorcelli E., Beraud E., Mathieu S., Lombardo D., Verine A. Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles. Int. J. Cancer 2009, 125:1016-1026.
89. Rountree R.B., Mandl S.J., Nachtwey J.M., Dalpozzo K., Do L., Lombardo J.R., Schoonmaker P.L., Brinkmann K., Dirmeier U., Laus R., Delcayre A. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011, 71:5235-5244.